Procoagulant platelets: Are they necrotic?

Blood

Volumn 116, Issue 12, 2010, Pages 2011-2018

  Jackson, Shaun P ^a   Schoenwaelder, Simone M ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCL2 RELATED PROTEIN A1; PROCOAGULANT; THROMBOCYTE ACTIVATING FACTOR;

APOPTOSIS; CALCIUM TRANSPORT; CELL DEATH; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOCYTE FUNCTION; THROMBOCYTE LIFESPAN; TISSUE REPAIR; BLOOD; BLOOD CLOTTING; NECROSIS; PATHOLOGY; PLATELET STORAGE POOL DEFICIENCY; THROMBOPHILIA;

APOPTOSIS; BLOOD COAGULATION; BLOOD PLATELETS; HUMANS; INFLAMMATION; NECROSIS; PLATELET STORAGE POOL DEFICIENCY; THROMBOPHILIA;

EID: 77957197351     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-261669     Document Type: Review

References (71)

1. Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128(6):1173-1186.
2. Zong WX, Thompson CB. Necrotic death as a cell fate. Genes Dev. 2006;20(1):1-15.
3. Festjens N, Vanden Berghe T, Vandenabeele P. Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim Biophys Acta. 2006;1757(9-10):1371- 1387. (Pubitemid 44472550)
4. Golstein P, Kroemer G. Cell death by necrosis: towards a molecular definition. Trends Biochem Sci. 2007;32(1):37-43. (Pubitemid 46043552)
5. Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol. 1995; 146(1):3-15.
6. Proskuryakov SY, Konoplyannikov AG, Gabai VL. Necrosis: a specific form of programmed cell death? Exp Cell Res. 2003;283(1):1-16.
7. Edinger AL, Thompson CB. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol. 2004;16(6):663-669. (Pubitemid 39463117)
8. Moquin D, Chan FK. The molecular regulation of programmed necrotic cell injury. Trends Biochem Sci. 2010;35(8):434-441.
9. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972; 26(4):239-257.
10. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med. 2009;361(16): 1570-1583.
11. Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14(5):943-951. (Pubitemid 46655455)
12. Schoenwaelder SM, Yuan Y, Josefsson EC, et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood. 2009;114(3):663-666.
13. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9(3):231-241.
14. Bouchier-Hayes L, Lartigue L, Newmeyer DD. Mitochondria: pharmacological manipulation of cell death. J Clin Invest. 2005;115(10):2640-2647. (Pubitemid 41434387)
15. Nakagawa T, Shimizu S, Watanabe T, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature. 2005;434(7033):652-658. (Pubitemid 40488558)
16. Nicotera P, Orrenius S. The role of calcium in apoptosis. Cell Calcium. 1998;23(2-3):173-180.
17. Brini M, Carafoli E. Calcium pumps in health and disease. Physiol Rev. 2009;89(4):1341-1378.
18. Sargeant P, Sage SO. Calcium signalling in platelets and other nonexcitable cells. Pharmacol Ther. 1994;64(3):395-443. (Pubitemid 24381230)
19. Varga-Szabo D, Braun A, Nieswandt B. Calcium signaling in platelets. J Thromb Haemost. 2009; 7(7):1057-1066.
20. Kulkarni S,Woollard KJ, Thomas S, Oxley D, Jackson SP. Conversion of platelets from a proaggregatory to a proinflammatory adhesive phenotype: role of PAF in spatially regulating neutrophil adhesion and spreading. Blood. 2007;110(6):1879-1886. (Pubitemid 47443900)
21. Kile BT. The role of the intrinsic apoptosis pathway in platelet life and death. J Thromb Haemost. 2009;7(suppl 1):214-217.
22. Leytin V, Allen DJ, Mykhaylov S, Lyubimov E, Freedman J. Thrombin-triggered platelet apoptosis. J Thromb Haemost. 2006;4(12):2656-2663.
23. Vanags DM, Orrenius S, Aguilar-Santelises M. Alterations in Bcl-2/Bax protein levels in platelets form part of an ionomycin-induced process that resembles apoptosis. Br J Haematol. 1997;99(4): 824-831. (Pubitemid 28047145)
24. Kulkarni S, Jackson SP. Platelet factor XIII and calpain negatively regulate integrin alphaIIbbeta3 adhesive function and thrombus growth. J Biol Chem. 2004;279(29):30697-30706. (Pubitemid 38938002)
25. Wolf BB, Goldstein JC, Stennicke HR, et al. Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation. Blood. 1999;94(5):1683-1692.
26. Remenyi G, Szasz R, Friese P, Dale GL. Role of mitochondrial permeability transition pore in coated-platelet formation. Arterioscler Thromb Vasc Biol. 2005;25(2):467-471. (Pubitemid 40189175)
27. Jobe SM, Wilson KM, Leo L, et al. Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. Blood. 2008;111(3):1257-1265. (Pubitemid 351213408)
28. Rosado JA, Redondo PC, Salido GM, Gomez-Arteta E, Sage SO, Pariente JA. Hydrogen peroxide generation induces pp60src activation in human platelets: evidence for the involvement of this pathway in store-mediated calcium entry. J Biol Chem. 2004;279(3):1665-1675.
29. Pignatelli P, Pulcinelli FM, Lenti L, Gazzaniga PP, Violi F. Hydrogen peroxide is involved in collagen-induced platelet activation. Blood. 1998;91(2): 484-490. (Pubitemid 28053370)
30. Polasek J. Platelet lysosomal acid phosphatase enzyme activity as a marker of platelet procoagulant activity. Blood Transfus. 2009;7(2):155-156.
31. Munnix IC, Cosemans JM, Auger JM, Heemskerk JW. Platelet response heterogeneity in thrombus formation. Thromb Haemost. 2009;102(6):1149-1156.
32. Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi. Microvasc Res. 1973;5(2):167-179.
33. Hess MW, Siljander P. Procoagulant platelet balloons: evidence from cryopreparation and electron microscopy. Histochem Cell Biol. 2001; 115(5):439-443. (Pubitemid 32467757)
34. Dale GL, Friese P, Batar P, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature. 2002;415(6868):175-179. (Pubitemid 34059519)
35. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost. 2005;3(10):2185-2192.
36. Heemskerk JW, Siljander P, Vuist WM, et al. Function of glycoprotein VI and integrin alpha2beta1 in the procoagulant response of single, collagen-adherent platelets. Thromb Haemost. 1999;81(5):782-792. (Pubitemid 29216567)
37. Heemskerk JW, Vuist WM, Feijge MA, Reutelingsperger CP, Lindhout T. Collagen but not fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity of adherent platelets: evidence for regulation by protein tyrosine kinase-dependent Ca2+ responses. Blood. 1997;90(7):2615-2625. (Pubitemid 27413471)
38. Ollgaard E. Macroscopic studies of platelet aggregation. Nature of an aggregating factor in red blood cells and platelets. Thromb Diath Haemorrh. 1961;6:86-97.
39. Wester J, Sixma JJ, Geuze JJ, van der Veen J. Morphology of the early hemostasis in human skin wounds: influence of acetylsalicylic acid. Lab Invest. 1978;39(3):298-311. (Pubitemid 9003902)
40. Leytin V, Freedman J. Platelet apoptosis in stored platelet concentrates and other models. Transfus Apher Sci. 2003;28(3):285-295. (Pubitemid 36506504)
41. Klinger MH. The storage lesion of platelets: ultrastructural and functional aspects. Ann Hematol. 1996;73(3):103-112.
42. Gulliksson H. Storage of platelets in additive solutions: the effect of citrate and acetate in in vitro studies. Transfusion. 1993;33(4):301-303. (Pubitemid 23134314)
43. Gulliksson H, Eriksson L, Hogman CF, Payrat JM. Buffy-coat-derived platelet concentrates prepared from half-strength citrate CPD and CPD whole-blood units. Comparison between three additive solutions: in vitro studies. Vox Sang. 1995;68(3): 152-159.
44. Koerner K, Sahlmen P, Zimmermann B, Cardoso M, Kubanek B. In vitro platelet function during storage in three different additive solutions. Vox Sang. 1994;67(2):154-159.
45. Koerner K, Weihe R, Sahlmen P, et al. Quality of pooled platelet concentrates prepared from buffy coats and stored in an additive solution after filtration. Ann Hematol. 1995;70(2):97-102.
46. Murphy S, Shimizu T, Miripol J. Platelet storage for transfusion in synthetic media: further optimization of ingredients and definition of their roles. Blood. 1995;86(10):3951-3960.
47. Zhang JG, Carter CJ, Culibrk B, et al. Buffy-coat platelet variables and metabolism during storage in additive solutions or plasma. Transfusion. 2008;48(5):847-856. (Pubitemid 351614913)
48. Plenchette S, Moutet M, Benguella M, et al. Early increase in DcR2 expression and late activation of caspases in the platelet storage lesion. Leukemia. 2001;15(10):1572-1581. (Pubitemid 32994676)
49. Bertino AM, Qi XQ, Li J, Xia Y, Kuter DJ. Apoptotic markers are increased in platelets stored at 37 degrees C. Transfusion. 2003;43(7):857-866.
50. Wong K, Li X. Nitric oxide infusion alleviates cellular activation during preparation, leukofiltration and storage of platelets. Transfus Apher Sci. 2004;30(1):29-39. (Pubitemid 38117292)
51. Bode AP, Holme S, Heaton WA, Swanson MS. Sustained elevation of intracellular cyclic 3′-5′ adenosine monophosphate is necessary for preservation of platelet integrity during long-term storage at 22 degrees C. Blood. 1994;83(5):1235-1243.
52. Mrowiec ZR, Oleksowicz L, Zuckerman D, et al. Buffy coat platelets stored in apyrase, aprotinin, and ascorbic acid in a suspended bag: combined strategies for reducing platelet activation during storage. Transfusion. 1996;36(1):5-10. (Pubitemid 26057257)
53. Rivera J, Lozano ML, Corral J, et al. Quality assessment of platelet concentrates supplemented with second-messenger effectors. Transfusion. 1999;39(2):135-143. (Pubitemid 29085133)
54. Wood EM, Colton E, Yomtovian RA, Currie LM, Connor J, Anderson JM. Prevention of monocyte adhesion and inflammatory cytokine production during blood platelet storage: an in vitro model with implications for transfusion practice. J Biomed Mater Res. 2000;51(2):147-154. (Pubitemid 30387629)
55. Ribeiro A, Swann JC, Berndt MC. Alterations of the levels of glycoproteins Ib-IX and IIb-IIIa in platelets stored at 22 degrees C. Thromb Res. 1992;66(6):619-627.
56. George JN. Changes in platelet membrane glycoproteins during blood bank storage. Blood Cells. 1992;18(3):501-511; discussion 512-505.
57. Bergmeier W, Burger PC, Piffath CL, et al. Metalloproteinase inhibitors improve the recovery and hemostatic function of in vitro-aged or -injured mouse platelets. Blood. 2003;102(12):4229-4235. (Pubitemid 37487012)
58. Eriksson L, Shanwell A, Gulliksson H, et al. Platelet concentrates in an additive solution prepared from pooled buffy coats. In vivo studies. Vox Sang. 1993;64(3):133-138.
59. Gulliksson H. Defining the optimal storage conditions for the long-term storage of platelets. Transfus Med Rev. 2003;17(3):209-215.
60. Dekkers DW, De Cuyper IM, van der Meer PF, Verhoeven AJ, de Korte D. Influence of pH on stored human platelets. Transfusion. 2007; 47(10):1889-1895.
61. Skripchenko A, Myrup A, Thompson-Montgomery D, Awatefe H, Moroff G, Wagner SJ. Periods without agitation diminish platelet mitochondrial function during storage. Transfusion. 2010;50(2):390-399.
62. Shrivastava M. The platelet storage lesion. Transfus Apher Sci. 2009;41(2):105-113.
63. Hartley PS, Savill JS, Brown SB. Hypoglycaemia predisposes platelets to death by affecting calcium homeostasis and mitochondrial integrity. Platelets. 2007;18(2):103-112.
64. Seghatchian J, Krailadsiri P. Platelet storage lesion and apoptosis: are they related? Transfus Apher Sci. 2001;24(1):103-105.
65. Albanyan AM, Harrison P, Murphy MF. Markers of platelet activation and apoptosis during storage of apheresis- and buffy coat-derived platelet concentrates for 7 days. Transfusion. 2009;49(1): 108-117.
66. Albrecht C, McVey JH, Elliott JI, et al. A novel missense mutation in ABCA1 results in altered protein trafficking and reduced phosphatidylserine translocation in a patient with Scott syndrome. Blood. 2005;106(2):542-549. (Pubitemid 40981249)
67. Bevers EM, Comfurius P, Dekkers DW, Harmsma M, Zwaal RF. Regulatory mechanisms of transmembrane phospholipid distributions and pathophysiological implications of transbilayer lipid scrambling. Lupus. 1998;7(suppl 2):S126-131. (Pubitemid 28484597)
68. Zwaal RF, Comfurius P, Bevers EM. Scott syndrome, a bleeding disorder caused by defective scrambling of membrane phospholipids. Biochim Biophys Acta. 2004;1636(2-3):119-128. (Pubitemid 38780788)
69. Galan AM, van Heerde WL, Escolar G, Ordinas A, Sixma J, de Groot PG. Antithrombotic action of annexin V proved as efficient as direct inhibition of tissue factor or thrombin. Eur J Clin Invest. 2006;36(9):633-639. (Pubitemid 44213830)
70. Reutelingsperger CP, Hornstra G, Hemker HC. Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. Eur J Biochem. 1985;151(3):625-629. (Pubitemid 16215799)
71. Kuypers FA, Larkin SK, Emeis JJ, Allison AC. Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity. Thromb Haemost. 2007;97(3):478-486.